Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis

Saara Huoponen, Kalle J. Aaltonen, Jaana Viikinkoski, Jarno Rutanen, Heikki Relas, Kirsi Taimen, Kari Puolakka, Dan Nordström, Marja Blom

Research output: Contribution to journalArticleScientificpeer-review

Original languageEnglish
Article number0220142
JournalPLoS One
Volume14
Issue number7
Number of pages14
ISSN1932-6203
DOIs
Publication statusPublished - 24 Jul 2019
MoE publication typeA1 Journal article-refereed

Fields of Science

  • MODIFYING ANTIRHEUMATIC DRUGS
  • NECROSIS-FACTOR INHIBITOR
  • COLLEGE-OF-RHEUMATOLOGY
  • EULAR RECOMMENDATIONS
  • MANAGEMENT
  • FAILURE
  • VALIDATION
  • SAFETY
  • LIFE
  • 3121 Internal medicine
  • 317 Pharmacy

Cite this